Literature DB >> 2857211

Precursor prothrombin status in patients receiving anticonvulsant drugs.

V A Davies, A D Rothberg, A C Argent, P M Atkinson, H Staub, N L Pienaar.   

Abstract

Protein induced by vitamin K absence (PIVKA) is the circulating prothrombin precursor found in considerable concentrations when carboxylation of prothrombin is impaired. In this study PIVKA-positivity was assessed in adult epileptic patients receiving a variety of anticonvulsant drugs. Mean PIVKA (+/- SD) concentration was 4.6 +/- 2.3% in 16 epileptics vs 1.1 +/- 0.7% in 10 age-matched controls (p less than 0.001). 13 of the 16 (81%) epileptics had PIVKA values above the highest value recorded for the controls (Fisher exact test, p less than 0.001). Other indices of coagulation were normal. There was no correlation between PIVKA concentration and the particular anticonvulsant taken. This study therefore shows that most epileptics on anticonvulsant therapy have a subclinical coagulation defect. These data, together with previous findings of raised PIVKA concentrations in maternal-infant pairs exposed to gestational anticonvulsants and reports of neonatal haemorrhage in infants of epileptics, strengthen the case for antenatal vitamin K supplementation in pregnancies complicated by anticonvulsant therapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2857211     DOI: 10.1016/s0140-6736(85)91901-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  4 in total

Review 1.  Anticonvulsants in pregnancy.

Authors:  R Meadow
Journal:  Arch Dis Child       Date:  1991-01       Impact factor: 3.791

2.  Prescribing in pregnancy. Epilepsy and anticonvulsant drugs.

Authors:  A Hopkins
Journal:  Br Med J (Clin Res Ed)       Date:  1987-02-21

3.  Hypoprothrombinemic hemorrhage due to cholestyramine therapy.

Authors:  A M Shojania; D Grewar
Journal:  CMAJ       Date:  1986-03-15       Impact factor: 8.262

4.  Hepatic enzyme induction and vitamin K1 elimination in man.

Authors:  A K Scott; B P Haynes; K D Schinkel; E E Ohnhaus; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.